5-HT3 antagonist antiemetic
Granisetron
Brand names: Kytril, Sancuso (patch)
Adult dose
Dose: PO 1–2mg OD-BD. IV 1–3mg slow before chemo. Patch (Sancuso): 1 patch 24–48h before chemo, leave for up to 7 days
Route: PO/IV/Transdermal
Frequency: OD-BD
Clinical pearls
- CINV (chemotherapy-induced) and PONV
- Lower QT effect than ondansetron
Contraindications
- Concurrent strong QT-prolonging drugs
- Hypersensitivity
Side effects
- Headache
- Constipation
- QT prolongation
- Serotonin syndrome with serotonergic agents
Interactions
- QT-prolonging drugs
- Serotonergic drugs
- Apomorphine (avoid — severe hypotension)
Monitoring
- ECG if QT risk
Reference: BNF; NICE TA313; ESMO antiemetic guidelines; https://bnf.nice.org.uk/drugs/granisetron/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015